239 related articles for article (PubMed ID: 10547558)
1. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
Deininger MH; Weller M; Streffer J; Meyermann R
Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
[TBL] [Abstract][Full Text] [Related]
2. Expression of Bcl-2 and Bax in oligodendrogliomas and their relationship to apoptosis.
Delgado MB; Anderson JR; Whittle IR; Wharton SB
Neuropathol Appl Neurobiol; 1999 Oct; 25(5):400-7. PubMed ID: 10564530
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
Reis-Filho JS; Faoro LN; Carrilho C; Bleggi-Torres LF; Schmitt FC
Cancer; 2000 Feb; 88(4):862-9. PubMed ID: 10679656
[TBL] [Abstract][Full Text] [Related]
4. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.
Kleinschmidt-DeMasters BK; Hashizumi TL; Sze CI; Lillehei KO; Shroyer AL; Shroyer KR
J Clin Pathol; 1998 Apr; 51(4):284-93. PubMed ID: 9659240
[TBL] [Abstract][Full Text] [Related]
5. BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.
Lytle RA; Jiang Z; Zheng X; Rich KM
J Neurooncol; 2004 Jul; 68(3):233-41. PubMed ID: 15332326
[TBL] [Abstract][Full Text] [Related]
6. Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Deininger MH; Grote E; Wickboldt J; Meyermann R
J Neurooncol; 2000 Jun; 48(2):121-9. PubMed ID: 11083075
[TBL] [Abstract][Full Text] [Related]
7. Role of apoptosis in the prognosis of oligodendrogliomas.
Schiffer D; Dutto A; Cavalla P; Chiò A; Migheli A; Piva R
Neurochem Int; 1997 Aug; 31(2):245-50. PubMed ID: 9220457
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression.
Deininger MH; Meyermann R; Trautmann K; Morgalla M; Duffner F; Grote EH; Wickboldt J; Schluesener HJ
Brain Res; 2000 Dec; 885(1):111-6. PubMed ID: 11121536
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival.
Varlet P; Guillamo JS; Nataf F; Koziak M; Beuvon F; Daumas-Duport C
Neuropathol Appl Neurobiol; 2000 Aug; 26(4):379-89. PubMed ID: 10931372
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
Park SH; Suh YL
Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
[TBL] [Abstract][Full Text] [Related]
13. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
[TBL] [Abstract][Full Text] [Related]
14. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
Laitinen KL; Soini Y; Mattila J; Pääkkö P
Cancer; 2000 Apr; 88(7):1590-8. PubMed ID: 10738217
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
18. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
[TBL] [Abstract][Full Text] [Related]
19. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of oligodendrogliomas.
Lebrun C; Fontaine D; Ramaioli A; Vandenbos F; Chanalet S; Lonjon M; Michiels JF; Bourg V; Paquis P; Chatel M; Frenay M;
Neurology; 2004 May; 62(10):1783-7. PubMed ID: 15159478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
